← Theravance Biopharma, Inc. TBPH
Market Price
$16.96
Market Cap
$871.76M
P/E Ratio
8.24
Revenue (FY 2025)
↑66.9% YoY
$107.46M
3-Yr CAGR: 27.9%
Net Income
↑287.7% YoY
$105.89M
Net Margin: 98.5%
Free Cash Flow
↑2,109.8% YoY
$238.50M
FCF Yield: 27.36%
EPS (Diluted)
↑279.1% YoY
$2.06
Basic: $2.10
Return on Equity
Efficiency
35.7%
ROA: 25.3%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (TBPH)
All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
- FY 2018: Revenue YoY (+292.4%) is identical to Gross Profit YoY (+292.4%). Verify the underlying Revenue and Gross Profit values for FY 2018 and FY 2017.
- FY 2019: Revenue YoY (+21.6%) is identical to Gross Profit YoY (+21.6%). Verify the underlying Revenue and Gross Profit values for FY 2019 and FY 2018.
- FY 2020: Revenue YoY (-2.1%) is identical to Gross Profit YoY (-2.1%). Verify the underlying Revenue and Gross Profit values for FY 2020 and FY 2019.
- FY 2021: Revenue YoY (-23.0%) is identical to Gross Profit YoY (-23.0%). Verify the underlying Revenue and Gross Profit values for FY 2021 and FY 2020.
- FY 2022: Revenue YoY (-7.2%) is identical to Gross Profit YoY (-7.2%). Verify the underlying Revenue and Gross Profit values for FY 2022 and FY 2021.
| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $48.6M | — | $45.8M | $-190.7M | — | — | — | $-99.0M | $-101.1M | — |
| FY 2017 | $15.4M | -68.4% | $9.4M | $-285.4M | -49.7% | — | — | $-201.1M | $-203.5M | -101.2% |
| FY 2018 | $60.4M | +292.4% | $36.7M | $-215.5M | +24.5% | — | — | $-112.9M | $-120.1M | +41.0% |
| FY 2019 | $73.4M | +21.6% | $44.6M | $-236.5M | -9.7% | — | — | $-238.2M | $-241.4M | -101.0% |
| FY 2020 | $71.9M | -2.1% | $43.7M | $-278.0M | -17.6% | — | — | $-250.4M | $-257.0M | -6.5% |
| FY 2021 | $55.3M | -23.0% | $33.6M | $-199.4M | +28.3% | $-2.87 | — | $-207.9M | $-211.3M | +17.8% |
| FY 2022 | $51.3M | -7.2% | $31.2M | $872.1M | +537.3% | $11.85 | +512.9% | $-187.0M | $-187.6M | +11.2% |
| FY 2023 | $57.4M | +11.8% | $14.1M | $-55.2M | -106.3% | $-1.00 | -108.4% | $-27.0M | $-29.5M | +84.3% |
| FY 2024 | $64.4M | +12.1% | $22.2M | $-56.4M | -2.2% | $-1.15 | -15.0% | $-11.5M | $-11.9M | +59.8% |
| FY 2025 | $107.5M | +66.9% | $70.0M | $105.9M | +287.7% | $2.06 | +279.1% | $238.5M | $238.5M | +2,109.8% |
Valuation
Market Price
$16.96
Market Cap
$871.76M
Enterprise Value
N/A
P/E Ratio
8.24
P/B Ratio
2.95
FCF Yield
27.36%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
65.18%
Operating Margin
3.35%
Net Margin
98.54%
Return on Equity (ROE)
35.69%
Return on Assets (ROA)
25.31%
Asset Turnover
0.26x
Revenue 3-Yr CAGR
27.91%
Financial Health & Liquidity
Current Ratio
10.93
Cash Ratio
4.38
Debt / Equity
N/A
Debt / Assets
N/A
Cash & Equivalents
$167.81M
Total Debt
N/A
Book Value / Share
$5.76
Cash Flow Efficiency
Operating Cash Flow
$238.54M
Capital Expenditures (CapEx)
$42.00K
Free Cash Flow
$238.50M
OCF / Revenue
221.97%
FCF / Revenue
221.93%
FCF 3-Yr CAGR
N/A
Per Share Metrics
EPS (Diluted)
$2.06
EPS (Basic)
$2.10
Dividends / Share
N/A
Book Value / Share
$5.76
EPS YoY Growth
279.13%
Balance Sheet (FY 2025)
Total Assets
$418.46M
Total Liabilities
$38.30M
Stockholders' Equity
$296.72M
Current Assets
$418.46M
Current Liabilities
$38.30M